UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.
PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.
Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.
A person in their early 30s has been using finasteride for about 10 years and recently started oral minoxidil, vitamin chewables, and dermarolling to address hair loss. They noticed pigmented vellus hairs and potential regrowth, questioning if oral minoxidil is more effective than topical due to enzyme differences.
The user has been using 1 mg finasteride for three months and recently started using 5% minoxidil once daily, resulting in new vellus hair growth. The user is hopeful that minoxidil will positively impact terminal hairs and is considering adding a derma stamp to the routine.